JPMorgan Chase & Co. Has $85.32 Million Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

JPMorgan Chase & Co. reduced its stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 4.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 462,170 shares of the medical research company's stock after selling 20,575 shares during the period. JPMorgan Chase & Co. owned approximately 0.90% of Charles River Laboratories International worth $85,317,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently modified their holdings of the stock. Versant Capital Management Inc raised its stake in shares of Charles River Laboratories International by 1,071.4% during the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock valued at $30,000 after acquiring an additional 150 shares during the last quarter. Pinnacle Bancorp Inc. increased its holdings in shares of Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after acquiring an additional 65 shares in the last quarter. Tortoise Investment Management LLC lifted its holdings in shares of Charles River Laboratories International by 77.7% in the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock worth $49,000 after purchasing an additional 115 shares in the last quarter. ORG Wealth Partners LLC bought a new position in shares of Charles River Laboratories International in the fourth quarter valued at $56,000. Finally, Wilmington Savings Fund Society FSB bought a new position in Charles River Laboratories International in the 3rd quarter valued at about $59,000. Institutional investors own 98.91% of the company's stock.

Remove Ads

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. The Goldman Sachs Group downgraded shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and decreased their price objective for the stock from $190.00 to $170.00 in a report on Friday, March 21st. Redburn Atlantic raised shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price target on the stock in a report on Monday, March 3rd. Citigroup upgraded Charles River Laboratories International from a "sell" rating to a "neutral" rating and boosted their target price for the stock from $155.00 to $175.00 in a research report on Tuesday, March 4th. William Blair downgraded shares of Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 22nd. Finally, UBS Group restated a "neutral" rating and issued a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. One analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the company. Based on data from MarketBeat.com, Charles River Laboratories International presently has a consensus rating of "Hold" and an average target price of $189.77.

Insider Activity at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 4,400 shares of the company's stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the transaction, the executive vice president now directly owns 20,013 shares in the company, valued at approximately $3,252,112.50. This represents a 18.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO James C. Foster acquired 6,075 shares of the stock in a transaction that occurred on Thursday, February 20th. The stock was purchased at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the transaction, the chief executive officer now owns 183,639 shares of the company's stock, valued at approximately $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 1.30% of the company's stock.

Charles River Laboratories International Price Performance

NYSE:CRL traded down $10.60 during mid-day trading on Tuesday, hitting $123.47. 1,586,279 shares of the company's stock traded hands, compared to its average volume of 780,873. The company has a market cap of $6.31 billion, a PE ratio of 823.13, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The firm's 50 day simple moving average is $160.28 and its 200 day simple moving average is $179.09. Charles River Laboratories International, Inc. has a 1 year low of $122.06 and a 1 year high of $258.56. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. During the same quarter in the previous year, the business posted $2.46 EPS. The business's quarterly revenue was down 1.1% on a year-over-year basis. Sell-side analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).